Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cystic Fibrosis (CF): full-pipeline trial registry
13 of 15 indexed Cystic Fibrosis (CF) trials are currently recruiting.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 13 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Cystic Fibrosis (CF): 15 US clinical trials tracked, 13 recruiting.
Cystic Fibrosis (CF) is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Indiana University, running 2 of these trials.
Enrollment posture brief
Registry condition cystic-fibrosis-cf
OPEN 13 | RECR 87% | LATE 2 | EARLY 3 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Brain Metastases, Adult (87% recruiting · 15 trials)
Cystic Fibrosis (CF) lists 13 open slots (87% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cystic Fibrosis (CF) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cystic Fibrosis (CF) is recruiting above its size-band peers.
13 of 15 indexed trials (86.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cystic Fibrosis (CF) trials is spread across many organizations.
Indiana University accounts for 2 of 15 trials (13.3%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Cystic Fibrosis (CF) trials plan to enrol fewer than 100 people.
Median target enrolment is 70 among the 15 trials that report a genuine target (sentinel values excluded). 10 of those (66.7%) plan for fewer than 100 participants.
-
Cystic Fibrosis (CF) splits between interventional and observational designs.
10 interventional and 5 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age
State University of New York at Buffalo
NCT07048574
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
University of Virginia
NCT06595420
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
University of Florida
NCT01851642
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
Jaeb Center for Health Research
NCT06837181
Ensuring Access to Optimal Therapy in CF: The ENACT Study
Arkansas Children's Hospital Research Institute
NCT07148739
CF Wellness Program
Johns Hopkins University
NCT07071324
CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis
Indiana University
NCT06642610
Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy
Indiana University
NCT06996951
Study With Phage for CF Subjects With Pseudomonas Lung Infection
BiomX
NCT06998043
ACT With CF Self-Help Toolkit
Thomas Jefferson University
NCT07436351
OnTrackCF: Engagement, Feasibility, and Acceptability Study
Boston Children's Hospital
NCT07031323
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
Nemours Children's Clinic
NCT06616857
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
Sionna Therapeutics
NCT07108153
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
Amgen
NCT00677365
: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)
National Jewish Health
NCT03445793
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cystic Fibrosis (CF) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cystic Fibrosis (CF) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cystic Fibrosis (CF) page
15 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Cystic Fibrosis (CF) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Indiana University sponsors the most Cystic Fibrosis (CF) trials on record, review their full trial history before evaluating a specific study. See Indiana University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cystic Fibrosis (CF) condition card totals 15 registered trials; most-linked intervention MP-376; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.